TORONTO, Jan. 16, 2019 /CNW/ - Pure Global Cannabis Inc.
(TSX.V:PURE; OTC: PRCNF; FRA:1QS) (the "Company" or "Pure
Global" an integrated, growth-oriented life sciences and
consumer products cannabis company, through its subsidiary
PureSinse Inc. ("PureSinse"), announces the launch of the
Clinical Cannabinoid Education Network, CCEN.ca, a not-for-profit,
to educate and inform physicians about the latest breakthroughs
related to medical cannabis.
The Clinical Cannabinoid Education Network (CCEN) provides an
educational platform for medical practitioners who want to learn
more about the science of cannabis and its place in their clinical
practice. By providing education and a forum for physicians by
physicians, they can share new information and learn from one
another in a supportive environment. This will allow more patients
to obtain the latest and most effective treatments as determined by
their doctors, including safe access to medical cannabis.
Run jointly as a partnership initiative between Spark Cannabis
and PureSinse, the CCEN launch features an initial networking
dinner on January 31, 2019 and a full
summit on May 10, 2019. Please visit
CCEN.ca to register.
On the CCEN advisory board is Dr. Sanjeev Goel. Dr. Goel is a practicing family
physician in Brampton, Ontario,
the Chief Medical Officer for PureSinse, and the medical director
for Spark Cannabis. Dr. Goel has extensive experience in medical
cannabis and has been a pioneer in the field since 2015. Dr. Goel
was also founder and CEO for an integrative medical practice using
cutting-edge medical treatments for patients across the country.
"We need an education network like this," says Dr. Goel. "By giving
doctors an opportunity to learn about medical cannabis from each
other, patients will be able to benefit from more effective
treatments overall."
For more information about CCEN, or to register for the
networking dinner and the summit, please visit CCEN.ca.
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSX.V:PURE; OTC:PRCNF; FRA:1QS) is an
innovation-based cannabis Company led by experienced pharma,
biotechnology, horticultural, consumer packaged goods (CPG), and
supply chain experts. The Company's wholly owned subsidiary,
PureSinse Inc., is a licensed producer under the Cannabis
Act, 2017. The Company's Brampton campus houses
facilities for vertically farmed cultivation, R&D, extraction,
manufacturing, and distribution. PURE will produce branded and
white-labeled cannabis products for the medical, pharmaceutical,
wellness, health & beauty, natural health, food & beverage,
and recreational legal markets with uniquely formulated and
purified concentrates. The Company is using the Canadian market as
a springboard to develop and manufacture GMP-compliant cannabis
products for international sale and distribution with a goal to
become one of the most trusted premium international cannabis
brands.
To register to Pure Global's mailing list, please
visit www.pureglobal.com. Follow @pureglobalcanna
on Twitter and Facebook and @pureglobalcannabis
on Instagram.
FORWARD-LOOKING STATEMENTS
This news release contains
certain forward-looking statements, including, but not limited to,
statements about Pure Global's future plans and intentions.
Wherever possible, words such as "may", "will", "should", "could",
"expect", "plan", "intend", "anticipate", "believe", "estimate",
"predict" or "potential" or the negative or other variations of
these words, or similar words or phrases, have been used to
identify these forward-looking statements. These statements reflect
management's current beliefs and are based on information currently
available to management as at the date hereof.
Forward-looking statements involve significant risk,
uncertainties and assumptions. Many factors could cause actual
results, performance or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
These factors should be considered carefully and readers should not
place undue reliance on the forward-looking statements. Although
the forward-looking statements contained in this news release are
based upon what management believes to be reasonable assumptions,
Pure Global cannot assure readers that actual results will be
consistent with these forward-looking statements. These
forward-looking statements are made as of the date of this news
release, and Pure Global assumes no obligation to update or revise
them to reflect new events or circumstances, except as required by
law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSXV)
accepts responsibility for the adequacy or accuracy of this
release.
SOURCE Pure Global Cannabis Inc.